



Palliative care support for prescribing in end-stage liver disease

Learn how treatment guidance from the Palliative Care Formulary is used by healthcare professionals to treat and manage the symptoms and common side effects of a patient with hepatic impairment.

Independent, specialist information, grounded in clinical practice



Palliative Care Formulary

Available through



**Medicines
Complete**



Palliative care support for prescribing in end-stage liver disease

Using essential knowledge at the point of care



John is a 55-year old man with end-stage liver disease as a result of long-term excessive alcohol consumption. A liver transplant is not an option and he has been referred to palliative care for symptom control.



PCF Hepatic impairment chapter provides details of chronic liver disease and the associated complications of hepatic encephalopathy, ascites and hepatorenal syndrome.

Medicines Complete

Hepatic impairment

Palliative Care Formulary
Publication last updated on 11-Apr-2023 >

The Palliative Care Formulary provides unrivalled and independent drug information for health professionals when caring for adult patients facing progressive life-limiting diseases and their care givers. This trusted source goes beyond standard drug reference works, empowering health professionals to select the right drugs and treatment regimens at the point of care to help improve quality of life.

Subsections

Related Content

Introduction

Pharmacological impact of hepatic impairment

Approach to prescribing in liver disease

Palliative care drugs for long-term use in chronic severe hepatic impairment

Simplifying long-term hepatic drugs

Last days of life

Hepatic impairment

Updated (minor change) June 2022

The recommendations in this chapter are *not* comprehensive, more a direction of travel than a detailed road map. Specific recommendations are limited to common classes and types of drugs used in palliative care. For other drugs, see the relevant monograph and the manufacturer's SPC. However, some SPCs are unnecessarily restrictive.¹

There will be occasions when hard evidence is not available, and clinicians may have to *prescribe and proceed with caution*, e.g:

- reduce polypharmacy as much as possible
- avoid hepatotoxic drugs if possible
- use a low starting dose
- reduce frequency of administration
- titrate upwards slowly
- monitor for both early and late onset toxicity (accumulation more likely if the plasma half-life is prolonged)
- ensure that the patient does not become constipated (may cause encephalopathy)

The Royal Pharmaceutical Society's Knowledge Business

2



The multidisciplinary palliative care team review John's case and discuss the planned treatment strategy. They are less familiar with treating patients with chronic severe hepatic impairment at the end of life. They want to know more about prescribing considerations for this group of patients.

How does end-stage liver disease affect the pharmacological impact of drugs?

The liver is the main site for the metabolism of most drugs. Although the hepatic reserve is large, chronic severe decompensated hepatic impairment (end-stage liver disease) affects the intrinsic activity and capacity of the metabolising enzymes, potentially leading to toxicity with hepatically metabolised drugs. Hepatic impairment can also cause changes within the body which can affect the absorption, distribution and elimination of drugs altering their action or overall clearance. Pharmacodynamic changes and secondary phenomena, e.g. altered receptor sensitivity, ascites, coagulopathy, hepatic encephalopathy, disruption of the blood-brain barrier and renal impairment can also affect the impact of drugs.

What considerations are needed when prescribing for patients with chronic severe hepatic impairment?

Hard evidence for specific dose recommendations is limited and the use of drugs in severe hepatic impairment may be off-label and/or contra-indicated. When deciding drug doses in hepatic impairment, it is important to consider the patient's overall clinical condition, rate of deterioration and goals of care, and not rely solely on liver function tests.

Essential drugs should not be withheld but high-risk patients should be closely monitored. Where drugs are deemed essential the following guidance is pragmatic:

- reduce polypharmacy as much as possible
- avoid hepatotoxic drugs if possible
- use a low starting dose
- reduce frequency of administration
- titrate upwards slowly
- monitor for both early and late onset toxicity (accumulation is more likely if the plasma half-life is prolonged)
- ensure that the patient does not become constipated (may cause hepatic encephalopathy)
- beware of sedation (may cause, worsen or mask hepatic encephalopathy).



PCF Hepatic impairment chapter provides details of the impact of hepatic impairment on drug pharmacology and general guidance on the approach to prescribing.




At his first clinic appointment, John is complaining of severe pain and following a full review of his symptoms, the team consider prescribing morphine.


What issues do the team need to consider when prescribing morphine for John?

There is an increased risk of toxicity with all opioids for patients with chronic severe hepatic impairment because of increased opioid receptor sensitivity and reduced integrity of the blood-brain barrier; further their sedative and constipating effects can worsen or sometimes mask hepatic encephalopathy.







The bio-availability and half-life of morphine are significantly increased in patients with chronic severe hepatic impairment. Both the starting dose and frequency of administration should be reduced and titrated slowly. Modified-release products should generally be avoided because of the prolonged duration of action.



PCF Hepatic impairment chapter provides guidance for prescribing drugs commonly used for long-term palliative care symptom relief in patients with chronic severe hepatic impairment with a prognosis of weeks—months or longer, including information on relative safety and specific prescribing advice and doses.



Medicines Complete

Palliative Care Formulary

Subsections Related Content

Introduction

Pharmacological impact of hepatic impairment

Approach to prescribing in liver disease

Palliative care drugs for long-term use in chronic severe hepatic impairment

Simplifying long-term hepatic drugs

Last days of life

Approach to prescribing in liver disease

Prescribing for a patient with liver disease should be individualised and pragmatic, balancing the risk vs. benefits in the context of overall goals of care. A cautious approach together with regular monitoring is required, particularly as the degree of impairment can fluctuate.

It is essential that prescribers are aware of the pharmacokinetics of the drug they are prescribing and the impact of hepatic impairment on drug pharmacology (**Box B**). Generally, the safer drugs are those with high PO bio-availability, minimal hepatic metabolism, low-moderate protein-binding, a short half-life, and no sedative, constipating or hepatotoxic effects.

Specific information on dose adjustment in patients with liver disease can be limited. SPCs often contain a blanket contra-indication (because of a lack of data) or provide nonspecific information.¹⁸Published guidance relies heavily on expert opinion and inevitably varies.¹⁷

PCF provides guidance for common palliative care drugs for long-term use in chronic severe hepatic impairment. Nonetheless, recommendations for dose adjustment can only be approximate and cannot replace careful clinical monitoring, including factors such as:

- underlying diagnosis/prognosis
- rate of disease progression
- changes in synthetic liver function/Child-Pugh score
- overall goals of care.

If in doubt, start with a low dose and titrate slowly to response (**Box C**).

Box C 'Red flags' for considering dose reduction in severe hepatic impairment ^{17, 18}



The team decide to start John on a low dose of oral immediate-release morphine.

What counselling points do the team need to discuss with John?

John and his carers should be made aware of the need to obtain urgent medical attention if any signs of toxicity develop, e.g. excessive sedation, respiratory depression or any of the features of worsening hepatic encephalopathy.

John should be warned not to increase the dose without contacting the team and not to drive or use tools or machines if feeling sleepy. He should also be warned that alcohol will have an additive sedative effect and he should avoid taking it.

Because of the risk of opioid-induced constipation, which may add to his risk of hepatic encephalopathy, John should closely monitor his bowel movements to ensure he produces two soft evacuations/day, adjusting his laxative regimen, when needed, within the parameters set by the team.

John should be warned that morphine may initially cause transient nausea lasting up to one week. He should be advised to contact the team to consider an anti-emetic if this becomes intolerable.

One week later, John returns for a clinic review. His mood is quite low, and the team consider whether to prescribe an antidepressant. However, after looking at the risk vs. benefit ratio of the use of antidepressants in chronic severe hepatic impairment, and after further discussion with John they decide to initially offer psychosocial support within the local day care team.

What are the risks of prescribing antidepressants for patients with chronic severe hepatic impairment and what is the antidepressant of choice for this group of patients?

Most antidepressants are significantly hepatically metabolised and highly protein-bound. These factors increase the risk of toxicity in patients with severe hepatic impairment. Several antidepressants cause sedation or constipation which can worsen or mask hepatic encephalopathy.

In palliative care, the first-line choice of antidepressant is generally sertraline or citalopram. Sertraline has very high first-pass metabolism and protein-binding; citalopram less so. Cautious use of low-dose citalopram is probably the best choice for patients with chronic severe hepatic impairment, unless they have additional risk factors for QT prolongation or severe cholestasis. SSRIs decrease platelet aggregation and increase the risk of GI bleeding, and are not a good choice in patients with coagulopathy or oesophageal varices. Additionally, citalopram has a significantly increased half-life in chronic severe hepatic impairment and the time taken to reach steady state and the emergence of undesirable effects may only become apparent after several weeks of regular use.




Nine months later John is admitted as an emergency to the hospice after significant rapid deterioration. A full assessment establishes that John is in the last days of his life and the team want to prescribe anticipatory drugs to ensure timely symptom control as needed.


What drugs are recommended for anticipatory prescribing in patients with end-stage hepatic impairment in the last days of life?

Currently, there are no national guidelines for prescribing in patients with severe or end-stage hepatic impairment in the last days of life. Consensus opinion, based on clinical experience, suggests the use of fentanyl or morphine for pain; fentanyl for breathlessness, with the addition of midazolam when there is concurrent anxiety; midazolam for agitation and restlessness; haloperidol for nausea and vomiting; haloperidol with or without midazolam for delirium; hyoscine butylbromide for noisy rattling breathing.


As most of these drugs have CNS depressant effects and may also cause constipation, one of the major challenges is to alleviate symptoms without precipitating or worsening hepatic encephalopathy. Thus, with all drugs, appropriate caution, close monitoring and individualized titration, initially with small doses, is required. Generally, subcutaneous injections are prescribed on an as needed basis to facilitate this.



PCF Hepatic impairment chapter provides suggested starting doses for drugs for common symptoms in the last days of life for a patient with end-stage hepatic impairment.



Hepatic impairment



+ Palliative Care Formulary

Subsections	Related Content
Introduction	
Pharmacological impact of hepatic impairment	
Approach to prescribing in liver disease	
Palliative care drugs for long-term use in chronic severe hepatic impairment	
Simplifying long-term hepatic drugs	
Last days of life	

Last days of life

Currently, there are no national guidelines for prescribing for patients with severe or end-stage hepatic impairment in the last days of life. [Box D](#) contains suggested starting doses for common symptoms based on consensus clinical experience. As the majority of drugs have CNS depressant effects + cause constipation, one of the major challenges is to alleviate symptoms without precipitating or worsening encephalopathy. Thus, with all drugs, appropriate caution, close monitoring and individualized titration, initially with small doses, is required. Generally, SC p.r.n. injections are prescribed to facilitate this.

Box D Anticipatory prescribing in patients with severe or end-stage hepatic impairment in the last days of life.

Starting doses given below are based on consensus clinical experience and take into account the risk of accumulation and toxicity; they may be lower than used in other circumstances; see individual drug monographs and [Reviewing medication when a patient is close to death](#). Generally, initial titration is with SC p.r.n. injections rather than CSCI.

Pain

In some liver units, fentanyl SC/CSCI is the first-line choice in patients with severe hepatic impairment, particularly when there is concurrent renal impairment (see [Opioids](#) section). However, it is uncertain if this outweighs the advantages of more cautious use of more familiar opioids in this setting. Starting dose in opioid-naïve patients:

- fentanyl 12.5–25microgram SC q1h p.r.n.
- morphine 2.5mg SC q1h p.r.n.



Palliative Care Formulary

Palliative Care Formulary (PCF) provides unrivalled and expert drug information for health professionals when caring for adult patients facing progressive life-limiting diseases. Tailored for use in palliative and hospice care settings, this trusted source goes beyond standard references, providing health professionals with in-depth and practical guidance on drugs and treatment regimens to help improve quality of life.

Access this essential knowledge today

MedicinesComplete makes it easy for health professionals to access essential medicines information at the point of care. Providing trusted evidence-based knowledge for confident decision-making and effective patient care.



Find out more today

For information and to contact our team
go to [PharmaceuticalPress.com](https://www.pharmaceuticalpress.com)

Available through



Disclaimer

MedicinesComplete is aimed at health professionals and assumes a level of professional training to interpret the information on this site. Information on the selection and clinical use of medicines is designed for prescribers, pharmacists and other health professionals and is not suitable for patients or the general public. All information should be interpreted in light of professional knowledge and supplemented as necessary with specialist publications, and all users are responsible for ensuring appropriate use or reliance on such information. Although RPS make reasonable efforts to update the information on MedicinesComplete, RPS make no representations, warranties or guarantees, whether express or implied, that the content is accurate, complete, or up to date. So far as permitted by law, RPS will not accept liability for damages, in any form, arising from or in relation to MedicinesComplete, or for a temporary inability to access this site. For more information please see our Website Terms and Conditions.

© The Royal Pharmaceutical Society, 2023. Copying of MedicinesComplete content without permission is not permitted.